

07-26-01

A

07/25/01

UTILITY PATENT APPLICATION
TRANSMITTAL

New nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.

P51160

First Named Inventor

Erskine, et al.

"EXPRESS MAIL CERTIFICATE"

EXPRESS MAIL MAILING LABEL NUMBER EL 737 870 295 US

DATE OF DEPOSIT: 25 July 2001

I hereby certify that this paper or fee and the papers indicated as being transmitted herewith are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date and with the Mailing Label Number indicated above and addressed to:

The Assistant Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.

NAME OF PERSON MAILING PAPER OR FEE

(TYPE OR PRINT)

EDWARD GIMMI

SIGNATURE

11002 U.S. PTO
09/19/2001
07/25/01

APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.	
1. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to Deposit Account No. <u>19-2570</u> <input checked="" type="checkbox"/> General Authorization to charge any and all fees under 37 CFR 1.16 or 1.17, including petitions for extensions of time, relating to this application. (37 CFR 1.136(a)(3)) (Submit an original, and a duplicate for fee processing)	7. <input checked="" type="checkbox"/> The Title of the Invention: COMPOUNDS AND METHODS FOR THE TREATMENT OF NEOPLASTIC DISEASE
2. <input checked="" type="checkbox"/> The total fee is calculated as shown below: Basic Filing fee \$710.00 Total Claims 38 - 20 = 18 x \$18 \$324.00 Independent Claims 4 - 3 = 1 x \$80 \$ 80.00 <input type="checkbox"/> Multiple Dependent Claim present. \$270 TOTAL FILING FEE \$1,114.00 <input type="checkbox"/> Cancel in this application original claims to of the prior application before calculating the filing fee.	8. <input type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission a. <input type="checkbox"/> Computer Readable Copy b. <input type="checkbox"/> Paper Copy (identical to computer copy) c. <input type="checkbox"/> Statement verifying identity of above copies d. <input type="checkbox"/> Use the identical computer-readable form filed in Application No. , filed as the computer-readable form for the instant application. (37 CFR 1.821(e))
3. <input checked="" type="checkbox"/> Charge \$1,114.00 to the above indicated Deposit Account.	ACCOMPANYING APPLICATION PARTS
3a. <input checked="" type="checkbox"/> Specification excluding Drawings [Total Pages] <u>45</u>	9. a. <input type="checkbox"/> Information Disclosure Statement (IDS)
3b. <input checked="" type="checkbox"/> Abstract on a separate sheet [Total Pages] <u>1</u>	b. <input type="checkbox"/> PTO-1449
4. <input type="checkbox"/> Drawing(s) (35 USC 113) [Total Sheets] _____	c. <input type="checkbox"/> Copies of all IDS Citations
5. <input checked="" type="checkbox"/> Declaration and Power of Attorney [Total Pages] <u>3</u> a. <input type="checkbox"/> Newly executed (original or copy) b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 17a completed) c. <input checked="" type="checkbox"/> Unsigned Declaration [Note Box 6 below] i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).	10. <input type="checkbox"/> Assignment Papers (cover sheet & document(s))
6. <input type="checkbox"/> Incorporation By Reference (useable if Box 5b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 5b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.	11. <input type="checkbox"/> Prior Application is Assigned to: (for continuation/divisional with Box 17a completed)
	12. <input type="checkbox"/> Preliminary Amendment [Total Pages]
	13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
	14. <input type="checkbox"/> Certified Copy of Priority Document(s) (if foreign priority is claimed)
	15. <input type="checkbox"/> Transfer all references cited by Applicants or by the Examiner from the parent Application Serial No. filed A PTO-1449 listing the references is enclosed.
	16. <input checked="" type="checkbox"/> Other: <u>Non-Publication Request</u>

17. <input type="checkbox"/> Priority Information, check appropriate box and supply the requisite information
a. The accompanying application is a <input type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application No: 0 filed 0.
b. <input checked="" type="checkbox"/> Benefit is claimed under Title 35, United States Code, Section 119(e) of the following Provisional Applications: Application No. 60/220,635, filed July 25, 2000.
c. <input type="checkbox"/> Please amend the specification by inserting before the first line the sentence: (37 CFR 1.78) This is a continuation/divisional of application Serial No. filed .

18. CUSTOMER NUMBER: 20462	19. RESPECTFULLY SUBMITTED,
Address GLAXOSMITHKLINE Corporate Intellectual Property - UW2220 P.O. Box 1539 King of Prussia, PA 19406-0939	Signature Name Edward R. Gimmi
Telephone (610) 270-4478 Fax (610) 270-5090	Registration No. 38,891

Date of Deposit: July 25, 2001

Attorney Docket No.: P51160

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Symon Erskine, *et al.*

25 July 2001

For: COMPOUNDS AND METHODS FOR THE TREATMENT OF
NEOPLASTIC DISEASE

Assistant Commissioner for Patents
Box Patent Application
Washington, D.C. 20231

NON-PUBLICATION REQUEST UNDER 35 U.S.C.
122(b)(2)(B)(i)

Sir:


I hereby certify that the invention disclosed in the attached application **has not and will not be** the subject of an application filed in another country, or under a multilateral international agreement, that requires publication at eighteen months after filing.

I hereby request that the attached application not be published under 35 U.S.C. 122(b).

This request must be signed in compliance with 37 CFR 1.33(b) and submitted with the application **upon filing**.

If applicant subsequently files an application directed to the invention disclosed in the attached application in another country, or under a multilateral international agreement, that requires publication of applications eighteen months after filing, the applicant **must** notify the United States Patent and Trademark Office of such filing within forty-five (45) days after the date of the filing of such foreign or international application. **Failure to do so will result in abandonment of the application (35 U.S.C. 122(b)(2)(B)(iii))**

Respectfully submitted,


Edward R. Gimmi
Attorney for Applicants
Registration No. 38,891

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-4478
Fax (610) 270-5090
N:\ERG\APPS\P51160\reqnonpub.doc